Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Esperion Therapeutics Inc.
Headquarters: Ann Arbor, MI, United States of America
Website: http://www.esperion.com
Year Founded: 2008
Status: Public
Industry Sector: HealthTechnology
CEO: Sheldon L. Koenig, MBA
Number Of Employees: 304
Enterprise Value: $858,251,083
PE Ratio: -5.62
Exchange/Ticker 1: NASDAQ:ESPR
Exchange/Ticker 2: N/A
Latest Market Cap: $296,773,504
BioCentury | Aug 17, 2024
Management Tracks
Mellman leaving gRED as part of oncology restructuring
Plus: Genmab creates two new C-suite positions, and updates from Esperion, Samsara and Armata
BioCentury | Apr 27, 2024
Data Byte
FDA label expansions: March brought full approvals of Elahere, Rybrevant
Plus: Approvals in earlier cancer lines for Rybrevant and Opdivo, and new indications for four more products
BioCentury | Jan 19, 2024
Finance
Public equity roundup: Edgewise shares get lift after $240M offering
Plus offerings by Immatics, Viridion, Alector, LegoChem and more
BioCentury | Mar 17, 2023
Product Development
March 16 Quick Takes: Merck latest to report disappointing TIGIT data
Plus: FDA panel reversal for DMD gene therapy sinks Sarepta shares and updates from Esperion, Everest and more
BioCentury | Mar 7, 2023
Deals
March 6 Quick Takes: Adaptimmune acquiring TCR2 Therapeutics
Plus: BridgeBio gains on oral achondroplasia therapy data and updates from Esperion, Aclaris, Merck & Co., Voyager and more
BioCentury | Dec 9, 2022
Finance
Dec. 8 Quick Takes: ADC play Dantari debuts with $47M led by Westlake
Plus: Sanofi ends SHP2 deal with Revolution and updates from Novartis, Daiichi, Takeda, Autolus, C-PATH and more
BioCentury | Apr 12, 2022
Management Tracks
Lowe’s Denton becomes CFO at Pfizer
Plus Werner named CEO at Alltrna, and updates from AptarGroup, MBX, Vesigen and more
BioCentury | Nov 10, 2021
Management Tracks
Wandeler to leave MorphoSys
Plus: Rubius, AstraZeneca, Landos, Nyxoah, Progenity and more
BioCentury | Oct 20, 2021
Product Development
Oct. 19 Quick Takes: Tymlos, vonoprazan and Tyvyt meet in Phase III
Plus Orexia, LogicBio, Esperion, MilliporeSigma and Intrivo
BioCentury | Oct 19, 2021
Management Tracks
Carl June joins Bioheng’s SAB
Plus: Myriad, Kura, Ideaya, IASO, OncoCyte and more
Items per page:
1 - 10 of 207